Meta is entering the AI-powered humanoid robot space, driven by Mark Zuckerberg’s vision and led by the Reality Labs hardware division. The initiative involves
Major American pharmaceutical companies are increasingly partnering with Chinese firms, with nearly 30% of large pharma deals in 2024 involving Chinese entities. Chinese advancements
Meta Platforms experiences a significant 23% surge in share prices this year, capturing investor attention. Analysts at Tigress Financial have revised the target price
Meta Platforms experienced a significant stock surge following a strong recovery since 2022, driven by innovation and strategic investments. Artificial intelligence forms the core
Salesforce and Palantir Technologies are key players poised to harness the potential of artificial intelligence in enterprise software. Salesforce faces challenges with irregular growth
Many doctors are transitioning from clinical roles to positions in tech firms and startups, drawn by higher salaries, better work-life balance, and reduced stress.
Robinhood Markets Inc is transitioning from a novice trading platform to a major financial services player. The company has expanded its offerings to include
Coca-Cola is leveraging AI and big data to enhance production processes and better predict consumer trends, boosting customer engagement and operational efficiency. The company
Warrior Met Coal, Inc.’s upcoming dividend payout is modest, with a yield of 1.7%, below the industry average. Forecasts indicate a potential 75.7% increase
Nvidia’s stock faced volatility in early 2025 due to market disruptions and new US chip restrictions. Despite uncertainties, a $500 billion investment in domestic
IBM is a key player among Dividend Aristocrats, maintaining over 25 years of consistent dividend increases. The company is evolving by shifting focus to
The mineral sector is critical for technological and infrastructural growth, with projected expansion from $2,260 billion in 2024 to $2,402 billion in 2025. Essential
Arm Holdings is rapidly transforming the tech landscape, particularly in the AI domain, after a successful stock market debut and tripling its IPO price.
Ascendis Pharma AS targets 2025 with growth-focused strategies after recent successes. Skytrofa has achieved a 6.5% market share in the US endocrinology sector. Transcon